Literature DB >> 16918569

Full scope of effect of facial lipoatrophy: a framework of disease understanding.

Benjamin Ascher1, Sydney Coleman, Tina Alster, Ute Bauer, Cheryl Burgess, Kimberly Butterwick, Lisa Donofrio, Peter Engelhard, Mitchel P Goldman, Philippe Katz, Danny Vleggaar.   

Abstract

BACKGROUND: Facial lipoatrophy has been observed to occur in a variety of patient populations, with inherited or acquired disease, or even in aging patients as a natural progression of tissue change over time. There is currently no framework from which physicians of all medical specialties can communally discuss the manifestations, diagnoses, and management of facial lipoatrophy.
OBJECTIVE: The aim of this assembly was to derive a definition of facial lipoatrophy capable of being applied to all patient populations and develop an accompanying grading system.
RESULTS: The final consensus of the Facial Lipoatrophy Panel encompasses both aging and disease states: "Loss of facial fat due to aging, trauma or disease, manifested by flattening or indentation of normally convex contours." The proposed grading scale includes five gradations (Grades 1-5; 5 being the most severe), and the face is assessed according to three criteria: contour, bony prominence, and visibility of musculature.
CONCLUSION: Categorizing the presentation of facial lipoatrophy is subjective and qualitative, and will need to be validated with objective measures. Furthermore, during the assembly, several topics were exposed that warrant further research, including the physiology of volume loss, age and lipoatrophy, and human immunodeficiency virus and lipoatrophy.

Entities:  

Mesh:

Year:  2006        PMID: 16918569     DOI: 10.1111/j.1524-4725.2006.32230.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  23 in total

1.  Global Volumetric Assessment and Three-Dimensional Enhancement of the Face With Injectable Poly-L-lactic Acid.

Authors:  Richard N Sherman
Journal:  J Clin Aesthet Dermatol       Date:  2010-08

2.  [Acute unilateral non-traumatic enophthalmus].

Authors:  J Mehlan; S Dulz; N Stübiger; F Schuettauf
Journal:  Ophthalmologe       Date:  2019-07       Impact factor: 1.059

3.  Optimizing injectable poly-L-lactic acid administration for soft tissue augmentation: The rationale for three treatment sessions.

Authors:  Ute Bauer; Miles H Graivier
Journal:  Can J Plast Surg       Date:  2011

4.  Treatment of Age-related Mid-face Atrophy by Injection of Cohesive Polydensified Matrix Hyaluronic Acid Volumizer.

Authors:  Patrick Micheels; Joan Vandeputte; Maria Kravtsov
Journal:  J Clin Aesthet Dermatol       Date:  2015-03

Review 5.  Approach to the human immunodeficiency virus-infected patient with lipodystrophy.

Authors:  Todd T Brown
Journal:  J Clin Endocrinol Metab       Date:  2008-08       Impact factor: 5.958

6.  Assessment of ultrasound for use in detecting lipoatrophy in HIV-infected patients taking combination antiretroviral therapy.

Authors:  Klaudija Viskovic; Ilana Richman; Ksenija Klasnic; Alexandra Hernandez; Ivan Krolo; George W Rutherford; Vanja Romih; Josip Begovac
Journal:  AIDS Patient Care STDS       Date:  2009-02       Impact factor: 5.078

7.  Sphenoid sinus expansion: a radiographic sign of intracranial hypotension and the sunken eyes, sagging brain syndrome (an American Ophthalmological Society thesis).

Authors:  Timothy J McCulley
Journal:  Trans Am Ophthalmol Soc       Date:  2013-09

8.  Management of Tear Trough with Hyaluronic Acid Fillers: A Clinical-Practice Dual Approach.

Authors:  Fernando Urdiales-Gálvez; Lisandro Farollch-Prats
Journal:  Clin Cosmet Investig Dermatol       Date:  2021-05-11

9.  Volumizing effects of a smooth, highly cohesive, viscous 20-mg/mL hyaluronic acid volumizing filler: prospective European study.

Authors:  Klaus Hoffmann
Journal:  BMC Dermatol       Date:  2009-08-27

10.  Principles of soft tissue augmentation for the aging face.

Authors:  Cheryl M Burgess
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.